This website is intended for U.S. Healthcare Professionals.
REVLIMID is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib. REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.
Lenalidomide
has
demonstrated
immunomodulatory,
antiangiogenic,
and antineoplastic
properties in vitro1
Lenalidomide properties:
1.
Immunomodulatory.
Immunomodulatory properties of lenalidomide have been shown to include increased number and activation of T cells and natural killer (NK) cells leading to direct and enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) via increased secretion of interleukin-2 and interferon-gamma, increased numbers of NKT cells, and inhibition of pro-inflammatory cytokines (e.g., TNF-α and IL-6) by monocytes.
2.
Antiangiogenic.
Lenalidomide has demonstrated antiangiogenic properties.
3.
Antineoplastic.
Lenalidomide inhibited proliferation and induced apoptosis of certain hematopoietic tumor cells including mantle cell lymphoma (MCL) in vitro.
